Genes, brain, and behavior
August 29, 2018
A Büki, G Horvath, G Benedek et al.
After peri-adolescence isolation rearing (IS) and subchronic ketamine (KET) treatment, adult, selectively bred Wistar rats (named WISKET) mimic abnormal behaviors reminiscent of human schizophrenia, including reduced prepulse-inhibition of startle reflex, disturbances in cognition, locomotor activity and thermoregulation, decreased pain sensitivity and electrophysiological alterations. To...
Schizophrenia Research
August 1, 2018
L Stan Leung, Jingyi Ma
We reviewed the participation of the septohippocampal system in an animal model of schizophrenia that was acutely induced by systemic injection of an N-methyl-d-aspartate (NMDA) receptor antagonist such as phencyclidine, MK-801 and ketamine. The NMDA receptor antagonist-induced model of schizophrenia is characterized by behavioral and electrophysiological disruptions, including a decrease in...
Frontiers in neuroendocrinology
July 2018
Alexia V Williams, Brian C Trainor
A roadblock to successful treatment for anxiety and depression is the high proportion of individuals that do not respond to existing treatments. Different underlying neurobiological mechanisms may drive similar symptoms, so a more personalized approach to treatment could be more successful. There is increasing evidence that sex is an important biological variable modulating efficacy of...
Frontiers in Psychiatry
May 14, 2018
Ben J Palanca, Hannah R. Maybrier, Angela M. Mickle et al.
16 citations
Electroconvulsive therapy (ECT) employs the elective induction of generalizes seizures as a potent treatment for severe psychiatric illness. As such, ECT provides an opportunity to rigorously study the recovery of consciousness, reconstitution of cognition, and electroencephalographic (EEG) activity following seizures. Fifteen patients with major depressive disorder refractory to pharmacologic...
Journal of Affective Disorders
April 15, 2018
Elizabeth D. Ballard, Julia S Yarrington, Cristan A Farmer et al.
Due to the heterogeneity of depressive symptoms-which can include depressed mood, anhedonia, negative cognitive biases, and altered activity levels-researchers often use a combination of depression rating scales to assess symptoms. This study sought to identify unidimensional constructs measured across rating scales for depression and to evaluate these constructs across clinical trials of a...
European Neuropsychopharmacology
April 2018
Francesc Artigas, Pau Celada, Analia Bortolozzi
In the second part we focus on two treatment strategies that may overcome the main limitations of current antidepressant drugs. First, we review the experimental and clinical evidence supporting the use of glutamatergic drugs as fast-acting antidepressants. Secondly, we review the involvement of microRNAs (miRNAs) in the pathophysiology of major depressive disorder (MDD) and the use of small...
Neuropsychopharmacology
February 5, 2018
Stephanie Thiebes, Saskia Steinmann, Stjepan Curic et al.
Auditory verbal hallucinations (AVH) are a common positive symptom of schizophrenia. Excitatory-to-inhibitory (E/I) imbalance related to disturbed N-methyl-D-aspartate receptor (NMDAR) functioning has been suggested as a possible mechanism underlying altered connectivity and AVH in schizophrenia. The current study examined the effects of ketamine, a NMDAR antagonist, on glutamate-related...
Journal of Psychoactive Drugs
2018
Nicholas Denomme
University of Michigan Pharmacology Professor Ed Domino is an expert in the field of neuropsychopharmacology. For over six decades, Dr. Domino has made many contributions to our understanding of psychoactive drugs, but is most well-known for his role in the development of ketamine anesthesia. This article covers the story behind this discovery, along with many other fascinating personal and...
Frontiers in Molecular Neuroscience
2018
Bartłomiej Pochwat, Bernadeta Szewczyk, Katarzyna Kotarska et al.
N-methyl-D-aspartate receptor (NMDAR) modulators induce rapid and sustained antidepressant like-activity in rodents through a molecular mechanism of action that involves the activation of Ca2+ dependent signaling pathways. Moreover, ketamine, a global NMDAR antagonist is a potent, novel, and atypical drug that has been successfully used to treat major depressive disorder (MDD). However, because...
Expert Review of Clinical Pharmacology
December 17, 2017
Alexander M. Sherwood, Thomas E Prisinzano
Disrupted mental health affects up to one in three individuals globally and is an unmet medical challenge contributing to individual suffering as well as significant societal and economic burden [1...